Donaldson Announces Integrated Lentiviral Vector Manufacturing Platform Development
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, announced its Isolere Bio (Isolere) and Univercells Technologies businesses are developing an integrated upstream and downstream platform for viral vector manufacturing.
- Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, announced its Isolere Bio (Isolere) and Univercells Technologies businesses are developing an integrated upstream and downstream platform for viral vector manufacturing.
- The first phase will focus on lentivirus (LV) manufacturing, concentrating on improving recoveries with a scalable process while keeping the manufacturing footprint small.
- “This manufacturing platform promises to establish a solution that accelerates process development timelines and reduces manufacturing complexity in the production of accessible cell and gene therapies worldwide,” said Andrew Dahlgren, Donaldson Life Sciences president.
- Mathias Garny, Univercells Technologies’ general manager, said, “scale-X technology is a demonstrated bioreactor platform for rapid process development and scale-up of virus manufacturing.